Downstream Decisions To Maximize Viral Vector Yields And Reduce COGs

This panel discussion explored the complex interplay of factors in downstream viral vector production that limit total vector recovery, as well as the tradeoffs between vector quality and quantity. The conversation featured Nathalie Clément, Ph.D., senior VP of vector development at Siren Biotechnology, and Hung Trinh, Ph.D., CEO at Vertex Biopharm Consulting. The panelists reflected on how teams are finding success in overcoming challenges in downstream purification, as well as how factors like vector type, dose, and route of administration can influence downstream design. They also discussed the biggest cost drivers in production that affect therapeutic sticker prices.